PanOptica to Present Positive Topical Anti-VEGF Eye Drop Data at OIS@AAO
MOUNT ARLINGTON, N.J.--(BUSINESS WIRE)--PanOptica announced that the company will present topline data from its Phase 1/2 clinical trial of PAN-90806 at the OIS@AAO on Thurs., Oct. 10, 2019